Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 1
2019 1
2020 1
2021 1
2022 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Immunoprofiling in Neuroendocrine Neoplasms Unveil Immunosuppressive Microenvironment.
Busse A, Mochmann LH, Spenke C, Arsenic R, Briest F, Jöhrens K, Lammert H, Sipos B, Kühl AA, Wirtz R, Pavel M, Hummel M, Kaemmerer D, Baum RP, Grabowski P. Busse A, et al. Among authors: lammert h. Cancers (Basel). 2020 Nov 19;12(11):3448. doi: 10.3390/cancers12113448. Cancers (Basel). 2020. PMID: 33228231 Free PMC article.
Classification of Molecular Subtypes of High-Grade Serous Ovarian Cancer by MALDI-Imaging.
Kassuhn W, Klein O, Darb-Esfahani S, Lammert H, Handzik S, Taube ET, Schmitt WD, Keunecke C, Horst D, Dreher F, George J, Bowtell DD, Dorigo O, Hummel M, Sehouli J, Blüthgen N, Kulbe H, Braicu EI. Kassuhn W, et al. Among authors: lammert h. Cancers (Basel). 2021 Mar 25;13(7):1512. doi: 10.3390/cancers13071512. Cancers (Basel). 2021. PMID: 33806030 Free PMC article.
Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer.
Keunecke C, Kulbe H, Dreher F, Taube ET, Chekerov R, Horst D, Hummel M, Kessler T, Pietzner K, Kassuhn W, Heitz F, Muallem MZ, Lang SM, Vergote I, Dorigo O, Lammert H, du Bois A, Angelotti T, Fotopoulou C, Sehouli J, Braicu EI. Keunecke C, et al. Among authors: lammert h. Gynecol Oncol. 2022 Aug;166(2):334-343. doi: 10.1016/j.ygyno.2022.06.010. Epub 2022 Jun 21. Gynecol Oncol. 2022. PMID: 35738917
High-accuracy determination of internal circadian time from a single blood sample.
Wittenbrink N, Ananthasubramaniam B, Münch M, Koller B, Maier B, Weschke C, Bes F, de Zeeuw J, Nowozin C, Wahnschaffe A, Wisniewski S, Zaleska M, Bartok O, Ashwal-Fluss R, Lammert H, Herzel H, Hummel M, Kadener S, Kunz D, Kramer A. Wittenbrink N, et al. Among authors: lammert h. J Clin Invest. 2018 Aug 31;128(9):3826-3839. doi: 10.1172/JCI120874. Epub 2018 Aug 6. J Clin Invest. 2018. PMID: 29953415 Free PMC article.
Protein kinase C targeting of luminal (T-47D), luminal/HER2-positive (BT474), and triple negative (HCC1806) breast cancer cells in-vitro with AEB071 (Sotrastaurin) is efficient but mediated by subtype specific molecular effects.
Albert V, Piendl G, Yousseff D, Lammert H, Hummel M, Ortmann O, Jagla W, Gaumann A, Wege AK, Brockhoff G. Albert V, et al. Among authors: lammert h. Arch Gynecol Obstet. 2022 Oct;306(4):1197-1210. doi: 10.1007/s00404-022-06434-2. Epub 2022 Mar 17. Arch Gynecol Obstet. 2022. PMID: 35298675 Free PMC article.
Response prediction in patients with gastric and esophagogastric adenocarcinoma under neoadjuvant chemotherapy using targeted gene expression analysis and next-generation sequencing in pre-therapeutic biopsies.
Kleo K, Jovanovic VM, Arndold A, Lehmann A, Lammert H, Berg E, Harloff H, Treese C, Hummel M, Daum S. Kleo K, et al. Among authors: lammert h. J Cancer Res Clin Oncol. 2023 Mar;149(3):1049-1061. doi: 10.1007/s00432-022-03944-z. Epub 2022 Mar 5. J Cancer Res Clin Oncol. 2023. PMID: 35246724 Free PMC article.
Concomitant inhibition of PI3K/mTOR signaling pathways boosts antiproliferative effects of lanreotide in bronchopulmonary neuroendocrine tumor cells.
von Hessert-Vaudoncourt C, Lelek S, Geisler C, Hartung T, Bröker V, Briest F, Mochmann L, Jost-Brinkmann F, Sedding D, Benecke J, Freitag H, Wolfshöfer S, Lammert H, Nölting S, Hummel M, Schrader J, Grabowski P. von Hessert-Vaudoncourt C, et al. Among authors: lammert h. Front Pharmacol. 2024 Feb 5;15:1308686. doi: 10.3389/fphar.2024.1308686. eCollection 2024. Front Pharmacol. 2024. PMID: 38375032 Free PMC article.
Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer.
Taromi S, Lewens F, Arsenic R, Sedding D, Sänger J, Kunze A, Möbs M, Benecke J, Freitag H, Christen F, Kaemmerer D, Lupp A, Heilmann M, Lammert H, Schneider CP, Richter K, Hummel M, Siegmund B, Burger M, Briest F, Grabowski P. Taromi S, et al. Among authors: lammert h. Oncotarget. 2017 Sep 23;8(57):97061-97078. doi: 10.18632/oncotarget.21221. eCollection 2017 Nov 14. Oncotarget. 2017. PMID: 29228593 Free PMC article.